The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Drug Updates / DMARDs & Immunosuppressives

DMARDs & Immunosuppressives

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

January 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

January 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

Can IL-6 Predict Sarilumab Response?

January 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

Bimekizumab Promising for PsA

December 18, 2018 • By Michele B. Kaufman, PharmD, BCGP

Long-Term Data Show Baricitinib Is Safe & Effective for RA

December 17, 2018 • By Michele B. Kaufman, PharmD, BCGP

Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

December 10, 2018 • By Michele B. Kaufman, PharmD, BCGP

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

December 3, 2018 • By Michele B. Kaufman, PharmD, BCGP

Rituximab Receives Label Update for ANCA-Associated Vasculitis

November 26, 2018 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Subcutaneous Tocilizumab for Ages 2–17

October 29, 2018 • By Michele B. Kaufman, PharmD, BCGP

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

October 22, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.